Rheumatoid Arthritis History Taking OSCE — DMARDs, DAS28, and Extra-articular Features

Why This Station Is Tested

Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a high-yield OSCE topic. Stations test your ability to take a focused rheumatological history, elicit extra-articular features, demonstrate knowledge of disease monitoring (DAS28), and counsel on disease-modifying drugs. RA also features in examination stations, prescribing OSCEs, and communication skills scenarios.

Opening the History

Introduce yourself and use an open question: "Can you tell me about your joint problems — when did they start and which joints are affected?" Allow the patient to give their account before directing the history. Note whether they use the words "stiffness," "pain," or "swelling" — RA typically presents with all three.

Core History Framework

Joint Symptoms

Morning stiffness: the hallmark of inflammatory arthritis. Ask: "When you wake up in the morning, do your joints feel stiff? How long does the stiffness last?" In RA, morning stiffness typically lasts >1 hour (often 1–2 hours or more) and improves with activity — this differentiates it from osteoarthritis (OA), where stiffness is brief (<30 minutes) and worsens with activity.

Joint pattern: RA classically involves small joints of the hands (MCP and PIP joints) and wrists symmetrically, with sparing of the DIP joints. Ask about each joint group systematically. Also commonly involved: MTPs of the feet (early), knees, shoulders, elbows, ankles. Cervical spine (atlanto-axial subluxation — serious). DIP sparing and symmetry distinguishes RA from psoriatic arthritis (DIP involvement, asymmetric) and OA (DIP involvement — Heberden's nodes).

SOCRATES for joints: onset (insidious vs acute), character (aching, throbbing), radiation, alleviating/aggravating factors, timing (morning worst), severity (VAS 0–10 or how it limits activity).

Functional impact: ability to open jars, button clothing, hold a pen, climb stairs, turn a key. Use HAQ (Health Assessment Questionnaire) questions in the OSCE: "On a scale of difficulty, how hard do you find it to: dress yourself, get up from a chair, eat, walk outdoors, do chores?"

Extra-articular Features

Ask specifically: "Have you had any problems with your eyes — dryness or redness? Any chest problems or breathlessness? Any skin lumps or nodules?"

Systems Review

Fatigue (extremely common in active RA — often underreported), weight loss (active disease), fever (active disease or intercurrent infection), dry eyes and dry mouth (secondary Sjögren's).

Drug History — DMARDs and Biologics

This is often a OSCE station in its own right. Know the key drugs:

Ask: "What medications are you taking for your arthritis? Have you had any problems with them? Do you have regular blood tests?" — monitoring compliance is a mark-scheme item.

DAS28 — Disease Activity Score

The DAS28 uses 28 joint count (tender and swollen), CRP or ESR, and patient global assessment (VAS 0–100). Score interpretation:

In the OSCE, demonstrate awareness: "I would calculate a DAS28 score to objectively quantify disease activity and guide treatment decisions."

Social History and Impact

Employment (does RA affect their ability to work?), occupational therapy referral, physiotherapy, carer needs, driving ability, mental health impact (depression is common in RA), and support systems.

Frequently Asked Questions

"How do I differentiate rheumatoid arthritis from osteoarthritis in the OSCE history?"

The key distinguishing features are: morning stiffness (RA: >60 minutes, improves with activity; OA: <30 minutes, worsens with activity), joint distribution (RA: MCP and PIP joints symmetrically, sparing DIP; OA: DIP — Heberden's nodes, PIP — Bouchard's nodes, first CMC, knees, hips), age of onset (RA: typically 30–50 years, any age; OA: usually >50 years), systemic features (RA: fatigue, weight loss, extra-articular features; OA: none), inflammatory markers (RA: raised CRP/ESR; OA: usually normal), serology (RA: RF positive in 70%, anti-CCP positive in 70–80%; OA: negative), and X-ray (RA: periarticular osteoporosis, joint space loss, erosions; OA: subchondral sclerosis, osteophytes, joint space loss, subchondral cysts). In the OSCE, using the duration of morning stiffness as the first discriminating question impresses examiners and is clinically practical.

"What is anti-CCP and why is it more specific than rheumatoid factor for RA?"

Anti-cyclic citrullinated peptide (anti-CCP) antibodies target citrullinated proteins and are generated in RA as part of the autoimmune process. Anti-CCP has a sensitivity of approximately 67–80% and specificity of 95–99% for RA, making it far more specific than rheumatoid factor (RF), which is positive in 70% of RA patients but is also present in 5–10% of healthy individuals, in other inflammatory conditions (SLE, Sjögren's, polymyositis), chronic infections (hepatitis C, subacute bacterial endocarditis, TB), and liver disease. Anti-CCP positivity before symptom onset predicts RA development and is associated with more erosive, aggressive disease. Seronegative RA (RF and anti-CCP both negative) occurs in approximately 20–30% of RA patients and still meets ACR/EULAR 2010 classification criteria on the basis of joint distribution, inflammatory markers, and imaging. In the OSCE, mentioning both RF and anti-CCP (and knowing that anti-CCP is more specific) will score well.

"What counselling points are essential when starting methotrexate for RA?"

Methotrexate is the anchor DMARD for RA and requires comprehensive counselling. Key points: (1) it takes 6–12 weeks to take full effect — continue current analgesia or NSAIDs in the interim; (2) must take folic acid 5mg once weekly (on a different day to methotrexate) to reduce mucositis and GI side effects; (3) regular blood monitoring: FBC, U&E, LFTs every 2 weeks until stable on a dose, then every 3 months — the patient needs a methotrexate monitoring book (shared care); (4) absolutely contraindicated in pregnancy and breastfeeding — effective contraception is mandatory for both men and women, and must stop at least 3 months before trying to conceive; (5) avoid live vaccines (BCG, MMR, yellow fever); (6) alcohol should be minimised (hepatotoxicity risk); (7) serious side effects to report immediately: breathlessness or dry cough (methotrexate pneumonitis — stop drug, seek urgent review), jaundice, unusual bruising or bleeding (bone marrow suppression), mouth ulcers. Always check baseline LFTs, FBC, and renal function before starting.

"What are the extra-articular manifestations of RA and which ones are the most clinically important?"

The most clinically significant extra-articular manifestation is cardiovascular disease — patients with RA have a 2-fold increased risk of cardiovascular events due to systemic inflammation accelerating atherosclerosis; this is the leading cause of premature death in RA. Pulmonary manifestations include interstitial lung disease (ILD — particularly in RF-positive, anti-CCP-positive disease; presents with progressive dyspnoea and dry cough), pleural effusions, and rheumatoid nodules on the lung (Caplan's syndrome in miners exposed to dust). Ocular: episcleritis (red eye, mild), scleritis (severe pain, can cause perforation — "scleromalacia perforans"), keratoconjunctivitis sicca (secondary Sjögren's). Haematological: normochromic normocytic anaemia of chronic disease, Felty's syndrome (RA + splenomegaly + neutropenia — increased infection risk). Neurological: peripheral neuropathy, mononeuritis multiplex, carpal tunnel syndrome, atlanto-axial subluxation (C1/C2 instability — dangerous in general anaesthesia; always ensure flexion/extension cervical spine X-rays are performed pre-operatively in RA patients).

"How would you counsel an RA patient who is considering starting anti-TNF therapy?"

Anti-TNF agents (e.g., adalimumab, etanercept, infliximab, certolizumab, golimumab) are biologic DMARDs indicated when conventional DMARDs (methotrexate ± combination) have failed after adequate trial (typically 6 months at maximum tolerated dose). Key counselling points: (1) screen for latent TB before starting — IGRA (interferon-gamma release assay) and chest X-ray; TB must be treated before commencing anti-TNF; (2) screen for hepatitis B and C — risk of reactivation; (3) avoid live vaccines while on anti-TNF; (4) increased infection risk — advise to seek prompt medical attention for any signs of infection (fever, cough, wound redness); (5) cannot use if active serious infection, severe heart failure (NYHA III/IV), or previous lymphoma (relative contraindication); (6) small increased risk of lymphoma; (7) risk of demyelination — caution in MS; (8) given by subcutaneous injection (adalimumab, etanercept) or IV infusion (infliximab) — discuss administration method; (9) may need to stop before surgery. Biologics are initiated and monitored by specialist rheumatologists through the NICE commissioning framework (NICE TA715).

"What is the ACR/EULAR 2010 classification criteria for RA and when do you use them?"

The 2010 ACR/EULAR classification criteria for RA use a scoring system of 0–10 across four domains: joint involvement (0–5 points — highest score for 10+ small joints), serology (0–3 points — high-positive RF or anti-CCP scores highest), acute phase reactants (0–1 — abnormal CRP or ESR), and duration of symptoms (0–1 — ≥6 weeks scores 1 point). A score of ≥6/10 classifies as definite RA. These criteria are designed for classifying patients in research studies rather than making an individual clinical diagnosis — a patient may have clinically evident RA without meeting all criteria, and vice versa. In clinical practice, diagnosis relies on history (morning stiffness >1 hour, symmetrical small joint involvement), examination, serology (RF, anti-CCP), and imaging (plain X-rays; MRI and ultrasound detect early erosions before X-ray changes). In the OSCE, citing the 2010 criteria by name demonstrates structured clinical knowledge.

Related guides: Musculoskeletal History OSCE · Hand Examination OSCE · GALS Screening Examination OSCE · Drug History OSCE · Osteoporosis OSCE